STING Activating Cyclic Dinucleotide Agonist MIW815

Drug Overview

STING activating cyclic dinucleotide agonist MIW815 is an advanced cancer medication designed to “jump-start” the body’s natural immune response against tumors. It belongs to a modern class of drugs known as STING agonists. In the medical community, MIW815 is considered a powerful form of Immunotherapy and a Targeted Therapy. It is often described as a “Smart Drug” because it specifically targets a pathway that the body normally uses to detect viruses, redirecting that power to find and destroy cancer cells.

This medication represents a significant shift in oncology. Instead of attacking the cancer directly with chemicals, it trains the patient’s own immune system to recognize the tumor as a threat. By doing this, it aims to create a long-lasting immune memory that can prevent the cancer from returning.

• Generic name: MIW815 (also known as ADU-S100)
• US Brand names: None (Currently an investigational drug)
• Drug Class: STING (Stimulator of Interferon Genes) Agonist; Immunotherapy
• Route of Administration: Intratumoral injection (injected directly into the tumor)
• FDA Approval Status: Investigational (Currently in clinical trials; not yet approved for general use)

What Is It and How Does It Work? (Mechanism of Action)

MIW815 works by mimicking a natural alarm signal in the body. To understand its function at the molecular level, we must look at a protein called STING, which stands for Stimulator of Interferon Genes.

The process follows these specific steps:

1. Detecting the Enemy: Normally, when a virus enters a cell, it leaves behind DNA. The body has a sensor called cGAS that finds this DNA and creates a messenger molecule called a cyclic dinucleotide (CDN).
2. Activating the Alarm: MIW815 is a synthetic version of this CDN messenger. When it is injected into a tumor, it bypasses the sensor and binds directly to the STING protein inside immune cells and cancer cells.
3. Signaling for Help: Once STING is activated, it triggers a signaling pathway through proteins called TBK1 and IRF3. This tells the cell to produce large amounts of Type 1 Interferons and other inflammatory chemicals called cytokines.
4. Calling in the Soldiers: These interferons act like a flare gun, calling “Dendritic Cells” to the tumor. These cells pick up pieces of the dead cancer cells and “show” them to T-cells, which are the body’s soldier cells.
5. Systematic Attack: The T-cells are now trained to recognize the cancer. They multiply and travel through the bloodstream to find and kill cancer cells, not just where the drug was injected, but throughout the entire body.

FDA-Approved Clinical Indications

As an investigational agent, MIW815 does not yet have official FDA approval for standard medical use. It is currently being used in international clinical trials for:

Oncological uses

• Investigational treatment for advanced, cutaneously accessible solid tumors (such as Melanoma).
• Investigational treatment for Squamous Cell Carcinoma of the Head and Neck.
• Investigational research for Lymphomas that have returned after treatment.
• Research into combination therapies with other “Checkpoint Inhibitors” like spartalizumab or pembrolizumab.

Non-oncological uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

In clinical research settings, MIW815 is administered as a liquid injected directly into a visible or reachable tumor by a specialist.

Dose Adjustments

Because this drug is injected directly into a tumor and acts locally before spreading, traditional dose adjustments for renal (kidney) or hepatic (liver) insufficiency are not yet standardized. However, patients with severe liver or kidney disease are monitored closely through blood tests before every injection. If a patient develops a severe “cytokine storm” or high fever, the next dose may be lowered or delayed.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 has focused on how well MIW815 works when paired with other modern immunotherapies.

Numerical data from Phase 1 and Phase 1b trials showed that the drug is active in the human body. In studies involving patients with advanced solid tumors or lymphomas, the “disease control rate” (the number of patients whose cancer shrank or stayed the same) was approximately 35 percent to 45 percent when MIW815 was used as a single agent. In combination studies with other “Smart Drugs,” research results showed that some patients who had stopped responding to all other treatments saw their tumors shrink by more than 30 percent. Current research results from 2024 suggest that the drug is most effective in tumors that are considered “inflamed,” or already have some immune cells present.

Safety Profile and Side Effects

Because MIW815 turns the immune system “on” very quickly, the side effects are usually related to inflammation.

Black Box Warning

There is no official Black Box Warning for MIW815, but it carries a strong warning regarding “Cytokine Release Syndrome” (CRS) and severe injection site reactions.

Common side effects

These occur in more than 10 percent of patients:

• Pain or swelling at the site of the injection
• Fever and chills (flu-like symptoms)
• Feeling very tired (fatigue)
• Nausea
• Headache

Serious adverse events

• Cytokine Release Syndrome: A dangerous overreaction of the immune system that causes very high fever and low blood pressure.
• Tumor Lysis Syndrome: When cancer cells die so fast that they release toxins into the blood, stressing the kidneys.
• Immune-mediated inflammation: This can affect healthy organs like the lungs (pneumonitis) or the liver (hepatitis).
• Severe ulceration at the injection site.

Management strategies

Most patients receive acetaminophen (Tylenol) before the injection to prevent fever. If a severe immune reaction occurs, doctors use steroid medications to quickly “turn down” the immune system. Patients are often observed in the clinic for several hours after the injection to monitor their blood pressure and temperature.

Research Areas

MIW815 is a primary focus in Research Areas involving “Combination Immunotherapy.” Scientists are studying if this drug can be paired with stem cell therapies to help patients with blood cancers. There is also significant research in the field of regenerative medicine looking at whether activating the STING pathway can help the body’s natural repair systems find and remove tiny clusters of “leftover” cancer cells after surgery. Currently, the most active research is looking at using MIW815 alongside modern “Cancer Vaccines” to make the vaccine much more powerful.

Disclaimer:

This information should be considered exploratory unless supported by definitive clinical evidence. While it represents significant frontiers in medical research, it is currently in the preclinical or early investigational phase and is not yet applicable to practical or professional clinical scenarios.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Imaging (CT or MRI) to identify the best tumor for injection.
• Complete Blood Count (CBC) and liver function tests.
• Baseline blood pressure and heart rate check.
• Pregnancy test for women of childbearing age.

Precautions during treatment

Patients should be aware that the injected tumor will likely become red, swollen, and painful. This is usually a sign that the “Smart Drug” is working and the immune system is attacking the area.

Do’s and Don’ts list

• Do tell your doctor immediately if you have a high fever or feel very dizzy after your injection.
• Do keep a record of any “flu-like” symptoms you experience at home.
• Do stay well-hydrated before and after your clinic visit.
• Don’t apply ice or heat to the injection site unless your doctor tells you to.
• Don’t take new herbal supplements without asking your oncology team first.
• Don’t miss your follow-up appointments, as the doctor needs to check if the other tumors in your body are shrinking.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. MIW815 is an investigational drug and is not approved by the Food and Drug Administration (FDA) for the treatment of any disease outside of clinical trials. Always consult with a qualified healthcare professional or your clinical trial oncologist before making any decisions regarding your medical treatment or managing side effects.